ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002.
The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback